Literature DB >> 22785258

Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.

Su-Jun Lee1, Joyce A Goldstein.   

Abstract

CYP3A4 and CYP3A5 require cytochrome b5 (b5) and NADPH-cytochrome P450 oxidoreductase (CPR) for optimum metabolism, but little is known about the specific requirements for b5 and CPR to produce optimal activities for these enzymes. The metabolism of testosterone (TT) by CYP3A4 and CYP3A5 was analyzed by various combinations of b5 and CPR using a fixed amount of recombinant P450 which had been purified from an Escherichia coli expression system. CYP3A4 and CYP3A5 required 4- and 8-fold more of CPR than of the P450s, respectively, for optimal activity. The requirement of b5 for optimal activity showed the same pattern for both CYP3A4 and CYP3A5, exhibiting a gradual stimulation of the activity reaching a maximum at 16 fold more b5 than P450. Although CYP3A4 exhibited higher activities than CYP3A5 in all combinations, both enzymes exhibited the same dependency profile for b5 and CPR. Therefore, the stronger activity of CYP3A4 compared to CYP3A5 appears to be intrinsic to the CYP3A4 protein itself and not to different requirements for b5 and CPR. Since the relative amounts of b5 and CPR are important in the maintenance of CYP3A4 and CYP3A5 activities, different levels of these proteins in vitro and in vivo may cause altered metabolism of their substrates or misinterpretation of enzyme properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785258      PMCID: PMC3602955          DOI: 10.2133/dmpk.dmpk-12-sh-030

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  25 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase.

Authors:  H Yamazaki; T Shimada; M V Martin; F P Guengerich
Journal:  J Biol Chem       Date:  2001-06-18       Impact factor: 5.157

3.  Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5.

Authors:  James R Reed; Paul F Hollenberg
Journal:  J Inorg Biochem       Date:  2003-01-15       Impact factor: 4.155

4.  Dynamic interactions of rabbit liver cytochromes P450IA2 and P450IIB4 with cytochrome b5 and NADPH-cytochrome P450 reductase in proteoliposomes.

Authors:  M Yamada; Y Ohta; G I Bachmanova; Y Nishimoto; A I Archakov; S Kawato
Journal:  Biochemistry       Date:  1995-08-15       Impact factor: 3.162

Review 5.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

6.  Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.

Authors:  Su-Jun Lee; Douglas A Bell; Sherry J Coulter; Burhan Ghanayem; Joyce A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2005-01-05       Impact factor: 4.030

7.  Role of cytochrome B5 in modulating peroxide-supported cyp3a4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity.

Authors:  Santosh Kumar; Dmitri R Davydov; James R Halpert
Journal:  Drug Metab Dispos       Date:  2005-05-03       Impact factor: 3.922

8.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.

Authors:  Su-Jun Lee; Khawja A Usmani; Brian Chanas; Burhan Ghanayem; Tina Xi; Ernest Hodgson; Harvey W Mohrenweiser; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2003-08

9.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

Authors:  Kiran C Patki; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

10.  Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli.

Authors:  H J Barnes; M P Arlotto; M R Waterman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

View more
  5 in total

Review 1.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

2.  Relation of Transcriptional Factors to the Expression and Activity of Cytochrome P450 and UDP-Glucuronosyltransferases 1A in Human Liver: Co-Expression Network Analysis.

Authors:  Shilong Zhong; Weichao Han; Chuqi Hou; Junjin Liu; Lili Wu; Menghua Liu; Zhi Liang; Haoming Lin; Lili Zhou; Shuwen Liu; Lan Tang
Journal:  AAPS J       Date:  2016-09-28       Impact factor: 4.009

3.  Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Shu-Ying Chang; Mary F Grubb; Chi-Chi Peng; Kenneth E Thummel; Nina Isoherranen; A David Rodrigues
Journal:  Drug Metab Dispos       Date:  2013-05-30       Impact factor: 3.922

Review 4.  The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Authors:  Nancy H C Loos; Jos H Beijnen; Alfred H Schinkel
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

5.  Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.

Authors:  Marie Stiborová; Radek Indra; Eva Frei; Kateřina Kopečková; Heinz H Schmeiser; Tomáš Eckschlager; Vojtěch Adam; Zbyněk Heger; Volker M Arlt; Václav Martínek
Journal:  Monatsh Chem       Date:  2017-07-04       Impact factor: 1.451

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.